Journal of International Oncology››2023,Vol. 50››Issue (7): 445-448.doi:10.3760/cma.j.cn371439-20230208-00086
Received:2023-02-08Revised:2023-06-07Online:2023-07-08Published:2023-08-03
| [1] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2021[M]. 北京: 人民卫生出版社, 2021: 70-75. |
| [2] | 武玲, 武晓旭, 冯慧晶, 等. 信迪利单抗联合IBI310治疗恶性黑色素瘤致重症免疫相关性心肌炎一例及文献分析[J]. 中国肿瘤生物治疗杂志, 2022, 29(11): 1013-1016. DOI: 10.3872/j.issn.1007-385x.2022.11.010. doi:10.3872/j.issn.1007-385x.2022.11.010 |
| [3] | Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923. doi:10.1001/jamaoncol.2018.3923pmid:30242316 |
| [4] | Bukamur H, Katz H, Alsharedi M, et al. Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab[J]. South Med J, 2020, 113(11): 600-605. DOI: 10.14423/SMJ.0000000000001166. doi:10.14423/SMJ.0000000000001166pmid:33140115 |
| [5] | Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019, 10: 108. DOI: 10.3389/fimmu.2019.00108. doi:10.3389/fimmu.2019.00108pmid:30778352 |
| [6] | Sears CR, Peikert T, Possick JD, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An official American Thoracic Society research statement[J]. Am J Respir Crit Care Med, 2019, 200(6): e31-e43. DOI: 10.1164/rccm.201906-1202ST. doi:10.1164/rccm.201906-1202ST |
| [7] | Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016, 22(24): 6051-6060. DOI: 10.1158/1078-0432.CCR-16-1320. doi:10.1158/1078-0432.CCR-16-1320pmid:27535979 |
| [8] | Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481. doi:10.1056/NEJMra1703481 |
| [9] | Zhai X, Zhang J, Tian Y, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients[J]. Cancer Biol Med, 2020, 17(3): 599-611. DOI: 10.20892/j.issn.2095-3941.2020.0102. doi:10.20892/j.issn.2095-3941.2020.0102pmid:32944393 |
| [10] | 陈双庆, 吴文博, 韩朝辉, 等. 免疫检查点抑制剂相关肺炎研究进展[J]. 肿瘤防治研究, 2022, 49(10): 1065-1070. DOI: 10.3971/j.issn.1000-8578.2022.22.0145. doi:10.3971/j.issn.1000-8578.2022.22.0145 |
| [11] | Li H, Ma W, Yoneda KY, et al. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report[J]. J Hematol Oncol, 2017, 10(1): 64. DOI: 10.1186/s13045-017-0433-z. doi:10.1186/s13045-017-0433-z |
| [12] | Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer[J]. JAMA Oncol, 2020, 6(6): 865-871. DOI: 10.1001/jamaoncol.2020.0726. doi:10.1001/jamaoncol.2020.0726pmid:32297899 |
| [13] | 段林立, 金川, 陈嵘, 等. 免疫检查点抑制剂相关肺炎22例临床特征分析[J]. 广州医科大学学报, 2022, 50(5): 12-18. DOI: 10.3969/j.issn.2095-9664.2022.05.03. doi:10.3969/j.issn.2095-9664.2022.05.03 |
| [14] | Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab[J]. Ann Oncol, 2017, 28(2): 368-376. DOI: 10.1093/annonc/mdw443. doi:10.1093/annonc/mdw443pmid:27687304 |
| [15] | Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J]. BMJ, 2018, 360: k793. DOI: 10.1136/bmj.k793. doi:10.1136/bmj.k793 |
| [16] | Pérol M. Multidisciplinary approach of immune checkpoint inhibitor-related pneumonitis: a key to address knowledge and management gaps[J]. J Thorac Oncol, 2020, 15(8): 1261-1264. DOI: 10.1016/j.jtho.2020.05.007. doi:S1556-0864(20)30393-2pmid:32718532 |
| [17] | Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature[J]. Cancer, 2018, 124(2): 271-277. DOI: 10.1002/cncr.31043. doi:10.1002/cncr.31043pmid:28960263 |
| [18] | Markham A. Envafolimab: first approval[J]. Drugs, 2022, 82(2): 235-240. DOI: 10.1007/s40265-022-01671-w. doi:10.1007/s40265-022-01671-wpmid:35122636 |
| [19] | Xu JM, Papadopoulos KP, Shimizu T, et al. Efficacy of envafolimab, a novel subcutaneous anti-PD-L1 inhibitor, in patients with advanced solid tumors: pooled results from three phase Ⅰ studies[C]. 2022 CSCO学术年会论文汇编, 北京: 中国临床肿瘤学会, 2022: 87-88. |
| [20] | Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(6): 552-562. DOI: 10.1016/S1470-2045(13)70093-7. doi:10.1016/S1470-2045(13)70093-7pmid:23598172 |
| [21] | Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115. DOI: 10.1056/NEJMoa1816047. doi:10.1056/NEJMoa1816047 |
| [22] | Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573. DOI: 10.1016/S1470-2045(20)30436-8. doi:10.1016/S1470-2045(20)30436-8pmid:33284113 |
| [23] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)肾癌诊疗指南 2022[M]. 北京: 人民卫生出版社, 2022: 50. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
